- Home
- VRAX vs CNSP Comparison
VRAX vs CNSP Comparison
Compare VRAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | CNSP |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 8.5M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VRAX | CNSP |
|---|---|---|
| Price | $2.75 | $5.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 481.2K | 7.9K |
| Earning Date | 06-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $1.90 |
| 52 Week High | $13.19 | $10.59 |
Technical Indicators
Market Signals| Indicator | VRAX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 52.49 |
| Support Level | $0.18 | $4.63 |
| Resistance Level | $3.10 | $6.07 |
| Average True Range (ATR) | 0.19 | 0.29 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 32.65 | 41.34 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.